SIGA Technologies (NASDAQ:SIGA) Announces Quarterly Earnings Results

SIGA Technologies (NASDAQ:SIGA) announced its quarterly earnings results on Thursday. The company reported $0.02 earnings per share (EPS) for the quarter, reports. SIGA Technologies had a return on equity of 51.40% and a net margin of 48.55%. The business had revenue of $10.01 million during the quarter.

SIGA Technologies Trading Down 0.8 %

SIGA Technologies stock traded down $0.06 during trading on Friday, hitting $7.57. 733,446 shares of the company were exchanged, compared to its average volume of 894,834. The business’s 50 day moving average is $7.31 and its 200 day moving average is $8.06. SIGA Technologies has a 52 week low of $4.26 and a 52 week high of $12.83. The company has a market capitalization of $540.27 million, a P/E ratio of 6.47 and a beta of 0.89.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. DekaBank Deutsche Girozentrale purchased a new position in shares of SIGA Technologies during the 2nd quarter valued at $40,000. China Universal Asset Management Co. Ltd. lifted its holdings in SIGA Technologies by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,727 shares of the company’s stock worth $93,000 after buying an additional 5,372 shares during the period. Bayesian Capital Management LP purchased a new stake in SIGA Technologies in the 1st quarter worth approximately $97,000. AQR Capital Management LLC purchased a new position in shares of SIGA Technologies in the 2nd quarter valued at approximately $99,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in SIGA Technologies by 38.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,684 shares of the company’s stock valued at $104,000 after buying an additional 3,829 shares during the last quarter. Institutional investors own 55.40% of the company’s stock.

About SIGA Technologies

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.